Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Confo Therapeutics, a Belgian start-up, has raised $33.4 million in series A financing from a suite of venture capital firms that includes Biogeneration Ventures and Wellington Partners. Confo is developing single-domain antibodies—sometimes called nanobodies—that are derived from camels. It plans to use the antibodies to target specific conformations of G protein–coupled receptors, a protein class involved in many nervous-system functions. Confo has partnerships with Lundbeck and Roche.
This article has been sent to the following recipient: